Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib vs Imatinib in Newly Diagnosed CML-CP
NCT03228303Phase 1Unknown
- Sponsor
- Assiut University
- Start
- Dec 2017
- Primary completion
- Jul 2020
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of nilotinib in chronic myeloid leukemia (CML) (2 arms), sponsored by Assiut University. Primary endpoints: Overall Survival Rate at 3 years, Cholesterol Level at 3 years and 2 more. Status: unknown.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03228303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03228303.